(Circulation. 1996;94:2216-2220.)
© 1996 American Heart Association, Inc.
Articles |
Anorexic Agents Aminorex, Fenfluramine, and Dexfenfluramine Inhibit Potassium Current in Rat Pulmonary Vascular Smooth Muscle and Cause Pulmonary Vasoconstriction
the Department of Medicine, Veterans Affairs Medical Center and University of Minnesota, Minneapolis, Minn.
Correspondence to Dr E. Kenneth Weir, Department of Medicine, VA Medical Center (111C), One Veterans Dr, Minneapolis, MN 55417.
Background The appetite suppressant aminorex fumarate is thought to have caused an epidemic of pulmonary hypertension in Europe in the 1960s. More recently, pulmonary hypertension has been described in some patients taking other amphetamine-like, anorexic agents: fenfluramine and its d-isomer, dexfenfluramine. No mechanism has been demonstrated that might account for the association between anorexic drugs and pulmonary hypertension.
Methods and Results Using the whole-cell, patch-clamp technique, we found that aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in smooth muscle cells taken from the small resistance pulmonary arteries of the rat lung. Dexfenfluramine causes reversible membrane depolarization in these cells. These actions are similar to those of hypoxia, which initiates pulmonary vasoconstriction by inhibiting a potassium current in pulmonary vascular smooth muscle. In the isolated, perfused rat lung, aminorex, fenfluramine, and dexfenfluramine induce a dose-related increase in perfusion pressure. When the production of endogenous NO is inhibited by N-nitro-L-arginine methyl ester, the pressor response to dexfenfluramine is greatly enhanced.
Conclusions These observations indicate that anorexic agents, like hypoxia, can inhibit potassium current, cause membrane depolarization, and stimulate pulmonary vasoconstriction. They suggest one mechanism that could be responsible for initiating pulmonary hypertension in susceptible individuals. It is possible that susceptibility is the result of the reduced production of an endogenous vasodilator, such as NO, but this remains speculative.
Key Words: hypertension, pulmonary • obesity • muscle, smooth • vasoconstriction
This article has been cited by other articles:
 |
|
 |
|
  N. W. Morrell, S. Adnot, S. L. Archer, J. Dupuis, P. Lloyd Jones, M. R. MacLean, I. F. McMurtry, K. R. Stenmark, P. A. Thistlethwaite, N. Weissmann, et al. Cellular and molecular basis of pulmonary arterial hypertension. J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S20 - S31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. McGoon and G. C. Kane Pulmonary Hypertension: Diagnosis and Management Mayo Clin. Proc., February 1, 2009; 84(2): 191 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Dempsie, I. Morecroft, D. J. Welsh, N. A. MacRitchie, N. Herold, L. Loughlin, M. Nilsen, A. J. Peacock, A. Harmar, M. Bader, et al. Converging Evidence in Support of the Serotonin Hypothesis of Dexfenfluramine-Induced Pulmonary Hypertension With Novel Transgenic Mice Circulation, June 3, 2008; 117(22): 2928 - 2937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. K. Weir, M. Obreztchikova, and Z. Hong Fenfluramine: riddle or Rosetta stone? Eur. Respir. J., February 1, 2008; 31(2): 232 - 235. [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Archer, M. Gomberg-Maitland, M. L. Maitland, S. Rich, J. G. N. Garcia, and E. K. Weir Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1{alpha}-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H570 - H578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Moreno, G. Frazziano, A. Cogolludo, L. Cobeno, J. Tamargo, and F. Perez-Vizcaino Role of Protein Kinase C{zeta} and Its Adaptor Protein p62 in Voltage-Gated Potassium Channel Modulation in Pulmonary Arteries Mol. Pharmacol., November 1, 2007; 72(5): 1301 - 1309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Kim, H. S. Ahn, B. H. Choi, H.-J. Jang, M.-J. Kim, D.-J. Rhie, S.-H. Yoon, Y.-H. Jo, M.-S. Kim, K.-W. Sung, et al. Open Channel Block of A-Type, Kv4.3, and Delayed Rectifier K+ Channels, Kv1.3 and Kv3.1, by Sibutramine J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 753 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Fike, M. R. Kaplowitz, Y. Zhang, and J. A. Madden Voltage-gated K+ channels at an early stage of chronic hypoxia-induced pulmonary hypertension in newborn piglets Am J Physiol Lung Cell Mol Physiol, December 1, 2006; 291(6): L1169 - L1176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Cohen How to write a patient case report. Am. J. Health Syst. Pharm., October 1, 2006; 63(19): 1888 - 1892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. V. McLaughlin and M. D. McGoon Pulmonary Arterial Hypertension Circulation, September 26, 2006; 114(13): 1417 - 1431. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Varghese, Z. Hong, and E. K. Weir Serotonin-Induced Inhibition of KV Current: A Supporting Role in Pulmonary Vasoconstriction? Circ. Res., April 14, 2006; 98(7): 860 - 862. [Full Text] [PDF]
|
|
|
|
|
|
A. Cogolludo, L. Moreno, F. Lodi, G. Frazziano, L. Cobeno, J. Tamargo, and F. Perez-Vizcaino Serotonin Inhibits Voltage-Gated K+ Currents in Pulmonary Artery Smooth Muscle Cells: Role of 5-HT2A Receptors, Caveolin-1, and KV1.5 Channel Internalization Circ. Res., April 14, 2006; 98(7): 931 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. K. Weir, J. Lopez-Barneo, K. J. Buckler, and S. L. Archer Acute Oxygen-Sensing Mechanisms. N. Engl. J. Med., November 10, 2005; 353(19): 2042 - 2055. [Full Text] [PDF]
|
|
|
|
 |
|
 W. K. P. Wong, J. A. Knowles, and J. H. Morse Bone Morphogenetic Protein Receptor Type II C-Terminus Interacts with c-Src: Implication for a Role in Pulmonary Arterial Hypertension Am. J. Respir. Cell Mol. Biol., November 1, 2005; 33(5): 438 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Hong, A. J. Smith, S. L. Archer, X.-C. Wu, D. P. Nelson, D. Peterson, G. Johnson, and E. K. Weir Pergolide Is an Inhibitor of Voltage-Gated Potassium Channels, Including Kv1.5, and Causes Pulmonary Vasoconstriction Circulation, September 6, 2005; 112(10): 1494 - 1499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rezaie-Majd, J. Murar, D. P. Nelson, R. F. Kelly, Z. Hong, I. M. Lang, A. Varghese, and E. K. Weir Increased release of serotonin from rat ileum due to dexfenfluramine Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2004; 287(5): R1209 - R1213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Newman, B. L. Fanburg, S. L. Archer, D. B. Badesch, R. J. Barst, J. G.N. Garcia, P. N. Kao, J. A. Knowles, J. E. Loyd, M. D. McGoon, et al. Pulmonary Arterial Hypertension: Future Directions: Report of a National Heart, Lung and Blood Institute/Office of Rare Diseases Workshop Circulation, June 22, 2004; 109(24): 2947 - 2952. [Full Text] [PDF]
|
|
|
|
|
|
M. Humbert, N. W. Morrell, S. L. Archer, K. R. Stenmark, M. R. MacLean, I. M. Lang, B. W. Christman, E. K. Weir, O. Eickelberg, N. F. Voelkel, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 13S - 24S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Weir, Z. Hong, and A. Varghese The Serotonin Transporter: A Vehicle to Elucidate Pulmonary Hypertension? Circ. Res., May 14, 2004; 94(9): 1152 - 1154. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lopez-Barneo, R. del Toro, K. L. Levitsky, M. D. Chiara, and P. Ortega-Saenz Regulation of oxygen sensing by ion channels J Appl Physiol, March 1, 2004; 96(3): 1187 - 1195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Hong, A. Olschewski, H. L. Reeve, D. P. Nelson, F. Hong, and E. K. Weir Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine Am J Physiol Lung Cell Mol Physiol, March 1, 2004; 286(3): L531 - L538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. I. Pozeg, E. D. Michelakis, M. S. McMurtry, B. Thebaud, X.-C. Wu, J. R.B. Dyck, K. Hashimoto, S. Wang, R. Moudgil, G. Harry, et al. In Vivo Gene Transfer of the O2-Sensitive Potassium Channel Kv1.5 Reduces Pulmonary Hypertension and Restores Hypoxic Pulmonary Vasoconstriction in Chronically Hypoxic Rats Circulation, April 22, 2003; 107(15): 2037 - 2044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Eddahibi, N. Morrell, M-P. d'Ortho, R. Naeije, and S. Adnot Pathobiology of pulmonary arterial hypertension Eur. Respir. J., December 1, 2002; 20(6): 1559 - 1572. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G Haworth PULMONARY HYPERTENSION IN THE YOUNG Heart, December 1, 2002; 88(6): 658 - 664. [Full Text] [PDF]
|
|
|
|
|
|
V. Hampl, J. Bibova, Z. Stranak, X. Wu, E. D. Michelakis, K. Hashimoto, and S. L. Archer Hypoxic fetoplacental vasoconstriction in humans is mediated by potassium channel inhibition Am J Physiol Heart Circ Physiol, December 1, 2002; 283(6): H2440 - H2449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Mitani, A. Mutlu, J. C. Russell, D. N. Brindley, J. DeAlmeida, and M. Rabinovitch Dexfenfluramine protects against pulmonary hypertension in rats J Appl Physiol, November 1, 2002; 93(5): 1770 - 1778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Malysz, G. Farrugia, Y. Ou, J. H. Szurszewski, A. Nehra, and S. J. Gibbons The Kv2.2 {alpha} Subunit Contributes to Delayed Rectifier K+ Currents in Myocytes From Rabbit Corpus Cavernosum J Androl, November 1, 2002; 23(6): 899 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Humbert, Z. Deng, G. Simonneau, R.J. Barst, O. Sitbon, M. Wolf, N. Cuervo, K.J. Moore, S.E. Hodge, J.A. Knowles, et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives Eur. Respir. J., September 1, 2002; 20(3): 518 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Caccitolo, H. M. Connolly, D. S. Rubenson, T. A. Orszulak, and H. V. Schaff Operation for anorexigen-associated valvular heart disease J. Thorac. Cardiovasc. Surg., October 1, 2001; 122(4): 656 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Perchenet, L. Hilfiger, J. Mizrahi, and O. Clement-Chomienne Effects of Anorexinogen Agents on Cloned Voltage-Gated K+ Channel hKv1.5 J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1108 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Glazer Long-term Pharmacotherapy of Obesity 2000: A Review of Efficacy and Safety Arch Intern Med, August 13, 2001; 161(15): 1814 - 1824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Belohlavkova, J. Simak, A. Kokesova, O. Hnilickova, and V. Hampl Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels J Appl Physiol, August 1, 2001; 91(2): 755 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Michelakis, E. K. Weir, X. Wu, A. Nsair, R. Waite, K. Hashimoto, L. Puttagunta, H. G. Knaus, and S. L. Archer Potassium channels regulate tone in rat pulmonary veins Am J Physiol Lung Cell Mol Physiol, June 1, 2001; 280(6): L1138 - L1147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Archer and S. Rich Primary Pulmonary Hypertension : A Vascular Biology and Translational Research "Work in Progress" Circulation, November 28, 2000; 102(22): 2781 - 2791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Hampl and J. Herget Role of Nitric Oxide in the Pathogenesis of Chronic Pulmonary Hypertension Physiol Rev, October 1, 2000; 80(4): 1337 - 1372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Bray and F. L. Greenway Current and Potential Drugs for Treatment of Obesity Endocr. Rev., December 1, 1999; 20(6): 805 - 875. [Abstract] [Full Text]
|
|
|
|
|
|
E. D. Michelakis, E. K. Weir, D. P. Nelson, H. L. Reeve, S. Tolarova, and S. L. Archer Dexfenfluramine Elevates Systemic Blood Pressure by Inhibiting Potassium Currents in Vascular Smooth Muscle Cells J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1143 - 1149. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Higenbottam, H. Marriott, G. Cremona, E. Laude, and D. Bee The Acute Effects of Dexfenfluramine on Human and Porcine Pulmonary Vascular Tone and Resistance Chest, October 1, 1999; 116(4): 921 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Reeve, S. L. Archer, M. Soper, and E. K. Weir Dexfenfluramine increases pulmonary artery smooth muscle intracellular Ca2+, independent of membrane potential Am J Physiol Lung Cell Mol Physiol, September 1, 1999; 277(3): L662 - L666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Rothman, M. A. Ayestas, C. M. Dersch, and M. H. Baumann Aminorex, Fenfluramine, and Chlorphentermine Are Serotonin Transporter Substrates : Implications for Primary Pulmonary Hypertension Circulation, August 24, 1999; 100(8): 869 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Salvi {alpha}1-Adrenergic Hypothesis for Pulmonary Hypertension Chest, June 1, 1999; 115(6): 1708 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Reeve, D. P. Nelson, S. L. Archer, and E. K. Weir Effects of fluoxetine, phentermine, and venlafaxine on pulmonary arterial pressure and electrophysiology Am J Physiol Lung Cell Mol Physiol, February 1, 1999; 276(2): L213 - L219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Egermayer, G I. Town, and A. J Peacock Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension Thorax, February 1, 1999; 54(2): 161 - 168. [Full Text]
|
|
|
|
|
|
A. P. Fishman Aminorex to Fen/Phen : An Epidemic Foretold Circulation, January 12, 1999; 99(1): 156 - 161. [Full Text] [PDF]
|
|
|
|
|
|
S. Hu, S. Wang, J. Gibson, and T. A. Gilbertson Inhibition of Delayed Rectifier K+ Channels by Dexfenfluramine (Redux) J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 480 - 486. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. G Haworth Primary pulmonary hypertension in childhood Arch. Dis. Child., November 1, 1998; 79(5): 452 - 455. [Full Text]
|
|
|
|
|
|
J. X.-J. Yuan, A. M. Aldinger, M. Juhaszova, J. Wang, J. V. Conte Jr, S. P. Gaine, J. B. Orens, and L. J. Rubin Dysfunctional Voltage-Gated K+ Channels in Pulmonary Artery Smooth Muscle Cells of Patients With Primary Pulmonary Hypertension Circulation, October 6, 1998; 98(14): 1400 - 1406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. ARCHER, K. DJABALLAH, M. HUMBERT, E. KENNETH WEIR, M. FARTOUKH, J. DALL'AVA-SANTUCCI, J.-C. MERCIER, G. SIMONNEAU, and A. TUAN DINH-XUAN Nitric Oxide Deficiency in Fenfluramine- and Dexfenfluramine-induced Pulmonary Hypertension Am. J. Respir. Crit. Care Med., October 1, 1998; 158(4): 1061 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-M. Gonzalez, A. P. L. Smith, C. J. Emery, and T. W. Higenbottam The Pulmonary Hypertensive Fawn-hooded Rat Has a Normal Serotonin Transporter Coding Sequence Am. J. Respir. Cell Mol. Biol., August 1, 1998; 19(2): 245 - 249. [Abstract] [Full Text]
|
|
|
|
|
|
S. EDDAHIBI, B. RAFFESTIN, J.-M. LAUNAY, M. SITBON, and S. ADNOT Effect of Dexfenfluramine Treatment in Rats Exposed to Acute and Chronic Hypoxia Am. J. Respir. Crit. Care Med., April 1, 1998; 157(4): 1111 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Connolly, J. L. Crary, M. D. McGoon, D. D. Hensrud, B. S. Edwards, W. D. Edwards, and H. V. Schaff Valvular Heart Disease Associated with Fenfluramine-Phentermine N. Engl. J. Med., August 28, 1997; 337(9): 581 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Curfman Diet Pills Redux N. Engl. J. Med., August 28, 1997; 337(9): 629 - 630. [Full Text]
|
|
|
|
 |
|
 U. D. McCann, L. S. Seiden, L. J. Rubin, and G. A. Ricaurte Brain Serotonin Neurotoxicity and Primary Pulmonary Hypertension From Fenfluramine and Dexfenfluramine: A Systematic Review of the Evidence JAMA, August 27, 1997; 278(8): 666 - 672. [Abstract] [PDF]
|
|